| Thu, 05 Dec 2019 13:50:01: | After Zantac scare, FDA targets generic metformin for carcinogen tests
|
| Wed, 04 Dec 2019 15:56:38: | DOJ inks price fixing settlement with small generics player. Will others follow?
|
| Wed, 04 Dec 2019 15:22:55: | Amgen snags another Enbrel outcomes-based payment deal as it seeks to prop up aging blockbuster
|
| Wed, 04 Dec 2019 15:19:35: | Pro-AbbVie bias may be driving rheumatologist confidence in newcomer Rinvoq: analyst
|
| Wed, 04 Dec 2019 14:31:50: | Pelosi pricing plan will yield 100 fewer new drugs, White House predicts
|
| Wed, 04 Dec 2019 09:23:06: | Roche's Tecentriq, chasing Merck's Keytruda, nabs another nod in all-important lung cancer
|
| Tue, 03 Dec 2019 22:28:40: | Horizon looks to the future with massive San Francisco manufacturing, R&D facility
|
| Tue, 03 Dec 2019 17:45:37: | Merck, insurers fight over $1.3B in damages from cyberattack: Bloomberg
|
| Tue, 03 Dec 2019 16:32:33: | Gilead's converting Truvada PrEP users to Descovy faster than expected: analyst
|
| Tue, 03 Dec 2019 15:54:23: | Blockbuster in the balance: Celgene's Reblozyl faces FDA committee for myelodysplastic syndromes
|
| Tue, 03 Dec 2019 14:23:01: | Merck's Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?
|
| Tue, 03 Dec 2019 14:19:10: | AstraZeneca offloads more Seroquel rights, this time to Cheplapharm for $42M
|
| Tue, 03 Dec 2019 14:09:17: | Pfizer bails on Irish pension overhaul after workers union rejection
|
| Mon, 02 Dec 2019 16:07:11: | Novartis' new cell therapy facility could ease manufacturing squeeze for CAR-T med Kymriah
|
| Mon, 02 Dec 2019 15:39:46: | AstraZeneca wins speedy FDA review for Imfinzi to challenge Roche in small cell lung cancer
|
| Mon, 02 Dec 2019 14:01:36: | China gives Merck, BMS cold shoulder on reimbursement list as PD-1 battle enters new phase
|
| Mon, 02 Dec 2019 13:54:49: | Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio
|
| Mon, 02 Dec 2019 02:01:09: | 2 November warning letters put FDA ad police on cusp of double-digit reprimands for 2019
|
| Wed, 27 Nov 2019 13:45:02: | FiercePharmaPolitics—Pelosi's plan a 'nuclear winter' for pharma, analyst says
|
| Wed, 27 Nov 2019 13:29:23: | Federal judge overturns part of Insys founder Kapoor's racketeering conviction
|
| Tue, 26 Nov 2019 23:16:56: | Johnson & Johnson, Teva, others face federal criminal probe into opioid sales: WSJ
|
| Tue, 26 Nov 2019 23:16:09: | Ex-Outcome Health execs hit with criminal charges alleging $1B fraud scheme
|
| Tue, 26 Nov 2019 20:32:31: | Johnson & Johnson can't get $70M Risperdal verdict tossed at Pennsylvania appeals court
|
| Tue, 26 Nov 2019 19:29:23: | Roche's flu med Xofluza drives drug resistance and may be a bad choice for kids, study says
|
| Tue, 26 Nov 2019 15:45:09: | ICER gets on board with AbbVie's Rinvoq for RA but frets over 'fair pricing' of next-gen drugs
|
